Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance
- PMID: 15642957
Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance
Abstract
Prior to the 2001 malarial treatment policy change in Tanzania, we conducted trials to assess the efficacy of sulfadoxine-pyrimethamine (SP) and the usefulness of molecular markers in monitoring resistance. A total of 383 uncomplicated Plasmodium falciparum malaria patients (between 6 and 59 months old) were treated with SP and their responses were assessed. Mutations in the P. falciparum dihydrofolate reductase (pfdhfr) and dihydropteroate synthase (pfdhps) genes in admission day blood samples were analyzed. Results indicated that 85.6% of the patients showed an adequate clinical response, 9.7% an early treatment failure, and 4.7% a late treatment failure. The quintuple mutant genotype (pfdhfr 51 Ile, 59 Arg, and 108 Asn and pfdhps 437 Gly and 540 Glu) showed an association with treatment outcome (odds ratio = 2.1; 95% confidence interval = 0.94-4.48, P = 0.045). The prevalence of the triple pfdhfr mutant genotype (51 Ile, 59 Arg, and 108 Asn) at a site of high SP resistance (23.6%) was four times higher compared with that observed at sites of moderate SP resistance (6.8-14.4%) (P = 0.000001). The genotype failure index calculated by using this marker was invariable (1.96-2.1) at sites with moderate SP resistance, but varied (3.4) at a site of high SP resistance. In conclusion, our clinical and molecular findings suggest that SP may have a short useful therapeutic life in Tanzania; thus, its adoption as an interim first-line antimalarial drug. The findings also point to the potential of the triple pfdhfr mutant genotype as an early warning tool for increasing SP resistance. These data form the baseline SP efficacy and molecular markers profile in Tanzania prior to the policy change.
Similar articles
-
Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania.Malar J. 2007 Jan 15;6:2. doi: 10.1186/1475-2875-6-2. Malar J. 2007. PMID: 17224049 Free PMC article.
-
Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville, Congo.Trop Med Int Health. 2007 Oct;12(10):1164-71. doi: 10.1111/j.1365-3156.2007.01904.x. Trop Med Int Health. 2007. PMID: 17956498
-
Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria.Acta Trop. 2005 Sep;95(3):183-93. doi: 10.1016/j.actatropica.2005.06.015. Acta Trop. 2005. PMID: 16023986
-
Origins and spread of pfdhfr mutant alleles in Plasmodium falciparum.Acta Trop. 2010 Jun;114(3):166-70. doi: 10.1016/j.actatropica.2009.07.008. Epub 2009 Jul 14. Acta Trop. 2010. PMID: 19607799 Review.
-
Sulfadoxine-pyrimethamine resistance in Plasmodium falciparum: a zoomed image at the molecular level within a geographic context.Acta Trop. 2013 Feb;125(2):163-90. doi: 10.1016/j.actatropica.2012.10.013. Epub 2012 Nov 3. Acta Trop. 2013. PMID: 23131424 Review.
Cited by
-
Occurrence of septuple and elevated Pfdhfr-Pfdhps quintuple mutations in a general population threatens the use of sulfadoxine-pyrimethamine for malaria prevention during pregnancy in eastern-coast of Tanzania.BMC Infect Dis. 2020 Jul 22;20(1):530. doi: 10.1186/s12879-020-05253-7. BMC Infect Dis. 2020. PMID: 32698764 Free PMC article.
-
High multiple mutations of Plasmodium falciparum-resistant genotypes to sulphadoxine-pyrimethamine in Lagos, Nigeria.Infect Dis Poverty. 2020 Jul 11;9(1):91. doi: 10.1186/s40249-020-00712-4. Infect Dis Poverty. 2020. PMID: 32653033 Free PMC article.
-
Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania.Malar J. 2007 Nov 11;6:146. doi: 10.1186/1475-2875-6-146. Malar J. 2007. PMID: 17996121 Free PMC article. Clinical Trial.
-
Impact of Malaria Control on Mortality and Anemia among Tanzanian Children Less than Five Years of Age, 1999-2010.PLoS One. 2015 Nov 4;10(11):e0141112. doi: 10.1371/journal.pone.0141112. eCollection 2015. PLoS One. 2015. PMID: 26536354 Free PMC article.
-
Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine-pyrimethamine in Tanzania.Malar J. 2016 Jun 23;15:335. doi: 10.1186/s12936-016-1387-2. Malar J. 2016. PMID: 27339129 Free PMC article.